GET DAILY SIGNALSNautilus Biotechnology (NAUT) Delivers Q3 Earnings Beat as Shares Drop -24.7%
Key Takeaways
- Nautilus Biotechnology reported a third quarter 2026 net loss of $15.6 million, or $0.12 per share, beating the consensus estimate of a $0.14 per share loss.
- Revenue of $0.2 million modestly exceeded expectations, driven by its Iterative Mapping Early Access Program and grant funding from The Michael J. Fox Foundation.
- Operating expenses rose 10% year over year to $16.9 million, while the net loss widened from $13.6 million in the prior-year quarter.
- Management raised its full-year 2026 revenue outlook, now expecting total revenue to exceed its earlier guidance of approximately $0.5 million.
- The company ended the quarter with $114.3 million in cash, cash equivalents, and investments, supporting a runway it expects to extend into early 2028.
Why This Quarter Matters
Nautilus Biotechnology is a development-stage life sciences company building the Voyager platform, a single-molecule proteomics system designed to quantify the proteome at unprecedented scale. Because the company is only just beginning to recognize revenue, this quarterly report matters less for near-term profitability and more for what it reveals about the pace of commercialization. In my view, investors are watching whether early access customers validate the technology, how grant funding ramps, and whether the company can control cash burn while it works toward a commercial launch. With instrument pre-orders targeted for early 2027 and shipments expected in mid-2027, this quarter offered an important progress check on the path from research tool to commercial product. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The Quarter in Numbers
For the third quarter ended September 30, 2026, Nautilus reported total revenue of $0.2 million, consisting primarily of grant revenue tied to its Michael J. Fox Foundation-funded alpha-synuclein assay work and service revenue from the Iterative Mapping Early Access Program. This figure slightly exceeded consensus estimates and marked a milestone as the company recognized its first revenue from both early access services and grant activity.
The company posted a net loss of $15.6 million, or $0.12 per share, compared with a net loss of $13.6 million, or $0.11 per share, in the same period last year. The reported loss per share came in ahead of the consensus estimate of a $0.14 loss. Operating expenses increased 10% year over year to $16.9 million, reflecting higher laboratory and professional services costs and increased salaries and related benefits, partially offset by lower facilities expenses.
Cash, cash equivalents, and investments totaled $114.3 million as of September 30, 2026, down from $129.2 million at the end of the second quarter, reflecting roughly $14.9 million in cash use during the period. On guidance, management now expects total 2026 revenue to exceed its prior outlook of approximately $0.5 million, with fourth quarter revenue expected to grow sequentially from the third quarter, excluding any potential contribution from its ARPA-H (Advanced Research Projects Agency for Health) funded SEEDS work.
Investor Reaction to the Results
Despite the top- and bottom-line beat, shares of NAUT declined sharply following the report, with the stock falling roughly 24.7% in the session. The move suggests investors focused less on the narrow earnings beat and more on the company's still-modest revenue scale, the year-over-year widening of its net loss, and rising operating expenses. Sentiment was also likely pressured by management's disclosure that it is exploring raising additional capital between now and mid-2027 to fund assay portfolio expansion, platform capabilities, and the build-out of its commercial team. For a pre-commercial company, execution milestones and cash position often carry more weight than a single quarter's loss, and the market's reaction reflects caution about the financing and timeline ahead of the Voyager launch.
What to Watch Going Forward
Looking ahead, the central catalyst for Nautilus is the commercial launch of the Voyager platform. Management expects to announce the launch and open pre-orders in early 2027, with instrument shipments and general availability of its tau and AKT1 assay kits targeted for mid-2027. Investors will be watching early access engagement, the conversion of early customers into commercial orders, and the pace at which additional oncology assays reach general availability.
On the financial side, the company's guidance that 2026 revenue will exceed its prior outlook of roughly $0.5 million provides a modest near-term benchmark, while single-digit full-year operating expense growth signals continued spending discipline. Cash runway, currently expected to extend into the first quarter of 2028, remains a key point of focus, particularly given the company's stated openness to raising capital ahead of the commercial ramp.
Broader industry dynamics also matter. Demand for high-resolution proteomics tools in drug discovery, biomarker research, and AI-driven biomedicine could support adoption, but the company must demonstrate that its reproducibility and throughput advantages translate into durable commercial traction. Progress on the SEEDS consortium, the Michael J. Fox Foundation collaboration, and publication-driven validation of the Iterative Mapping method will all serve as important signals of scientific and commercial momentum in the quarters ahead.
How I Use Tickeron Tools for Research
In my research process, I often turn to Tickeron’s AI Screener to compare companies like NAUT against peers. It helps filter based on various metrics and surface setups that match specific criteria, which adds useful context when evaluating development-stage names.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
NAUT in upward trend: 10-day moving average broke above 50-day moving average on September 30, 2026
The 10-day moving average for NAUT crossed bullishly above the 50-day moving average on September 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 16 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on September 28, 2026. You may want to consider a long position or call options on NAUT as a result. In 73 of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.
NAUT moved above its 50-day moving average on September 28, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +38.03% 3-day Advance, the price is estimated to grow further. Considering data from situations where NAUT advanced for three days, in 208 of 252 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
The Aroon Indicator entered an Uptrend today. In 144 of 177 cases where NAUT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 81%.
Bearish Trend Analysis
The 10-day RSI Indicator for NAUT moved out of overbought territory on October 26, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 29 similar instances where the indicator moved out of overbought territory. In 26 of the 29 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NAUT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
NAUT broke above its upper Bollinger Band on October 23, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. NAUT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 95 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 98 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.805) is normal, around the industry mean (2.974). P/E Ratio (-6.422) is within average values for comparable stocks, (-0.899). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.903) among similar stocks. NAUT's P/S Ratio (10000.000) is very high in comparison to the industry average of (439.237).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NAUT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement